Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.

Yasuhiro Kodera,Naoto Takahashi,Takaki Yoshikawa,Nobuhiro Takiguchi,Kazumasa Fujitani,Yuichi Ito,Katsufumi Miyamoto,Osamu Takayama,Motohiro Imano,Daisuke Kobayashi,Yumi Miyashita,Satoshi Morita,Junichi Sakamoto

Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.

2017

Yasuhiro Kodera
Naoto Takahashi
Takaki Yoshikawa
Nobuhiro Takiguchi
Kazumasa Fujitani
Yuichi Ito
Katsufumi Miyamoto
Osamu Takayama
Motohiro Imano
Daisuke Kobayashi
Yumi Miyashita
Satoshi Morita
Junichi Sakamoto

Background Peritoneal carcinomatosis is common after curative resection of gastric cancer. Intraperitoneal administration of paclitaxel (PTX) is known to control ovarian peritoneal metastases.

Keywords:

Urology
General surgery
Randomized controlled trial
Medicine
Tegafur
Gastrectomy
Peritoneal Neoplasm
Cancer
Paclitaxel
Radical surgery
Survival rate
Surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations